Articles tagged with Leukemia
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
A $7 million funding boost will help researchers better understand hairy cell leukemia and develop more effective treatments, particularly for patients with variant disease and those who relapse. The grants will focus on improving patient outcomes and closing the gap in treatment options.
A phase 2 clinical trial found that vitamin C supplements reduced the frequency of anemia, pneumonia, and internal bleeding in patients with pre-cancer blood disorders. The study suggests that vitamin C may improve outcomes in these patients, warranting further investigation in a phase 3 trial.
Acute myeloid leukemia (AML) remains difficult to treat with immunotherapy due to its ability to evade the immune system. The study aims to understand how immune cells recognize leukemia cells without relying on HLA, with the goal of developing HLA-independent immunotherapies.
The 2026 Josep Carreras Institute Symposium explores the latest immunology advances in haematological malignancies, transforming treatment landscapes with CAR-T therapies and checkpoints. Major challenges remain in understanding tumour-immune system interactions and therapeutic resistance.
Researchers developed a new treatment for acute myeloid leukemia (AML) by using AcTor, a molecule that inhibits a signalling protein, in combination with ixazomib. The treatment successfully eliminated cancer cells and leukemic stem cells, showing promising results in mice studies.
A phase 2 clinical trial found that a less-intensive combination of azacitidine and venetoclax was more effective in treating acute myeloid leukemia, with patients tolerating treatment better and spending less time in the hospital. The combination also led to more patients reaching stem cell transplantation.
The Josep Carreras Institute has joined BLOODPAC to advance liquid biopsy research and clinical implementation. As a member, the Institute will collaborate with leading partners to develop standards, validation protocols, and access the BLOODPAC Portal for knowledge sharing.
The Leukemia Research Foundation has funded a two-year, $150,000 research project at the University of Cincinnati to develop a new treatment for TP53-mutated leukemia. The project aims to identify RhoA as a potential therapeutic vulnerability, which could make the leukemia more sensitive to existing treatments.
Advances in blood cancer treatment have saved 25.8 million life-years, with significant gains for Hodgkin lymphoma and non-Hodgkin lymphoma patients. However, Black patients and those with acute myeloid leukemia (AML) continue to experience worse outcomes, highlighting the need for continued research investment.
UCSF scientists have invented a way to treat cancer with teacher cells and tumor pieces, combining immune cells grown in the lab with patient tumor samples. The method uses dendritic cells to train T cells to recognize and destroy cancer cells, offering a promising approach to immunotherapy.
Researchers developed a first-in-class therapy targeting MYC, a protein involved in 70% of cancers, by disrupting its relationship with GSPT1. This approach showed strong anti-cancer activity in multiple types of blood cancers, including treatment-resistant models.
A new study suggests that younger, less genetically matched donors can produce encouraging outcomes for blood cancer patients. Researchers found that carefully selected mismatched donors can produce favorable outcomes, potentially widening access to a potentially lifesaving transplant.
Researchers identified NUDT5 as a key player in the molecular mechanisms determining whether cells succumb to or survive 6-TG. Targeted protein degradation revealed that degrading NUDT5 protects cells from the drug's toxic effects.
A large study reveals that dexrazoxane significantly reduces heart damage caused by chemotherapy in pediatric cancer patients years after treatment. The findings could change how doctors follow survivors for decades and provide families with reassurance about long-term effects.
A new study published in JNCCN finds that a cost-effective education program targeting survivors and their doctors can increase screening rates for skin cancer. The study showed that practical solutions can close the gap between elevated risks and low screening rates, especially after transitioning out of specialty care.
New research from Memorial Sloan Kettering Cancer Center sheds light on leukemia resistance to promising new drugs and the role of bone hardness in the immune battle against metastasis. A telehealth tobacco treatment program also shows promise in helping cancer patients quit smoking.
Researchers identified a rare genetic mutation, BTK A428D, that blocks both BTK inhibitors and next-generation BTK degraders. The study provides new insight into how cancers evolve under treatment pressure and may help develop strategies to overcome resistance in patients with chronic lymphocytic leukemia.
Research reveals that patients' inherited genetic variants can impact the benefits and toxicity of CAR-T cell therapy for blood cancers. Variants in genes such as STXBP2, ADAMTSL3, and PTPN22 were found to correlate with treatment-related toxicity or enhanced therapeutic activity.
Researchers identified RBM5 as a potential vulnerability in childhood leukemias, particularly in cancer stem cells. Removing RBM5 from these cells doubled mouse model survival rates and showed promise for developing more precise therapies. Targeting RBM5 may disrupt the pro-growth feedback loop of MYC, a key cancer-driving protein.
Associate Professor Laurence Cheung has been recognized for his groundbreaking research in developing more effective treatments for children with high-risk leukaemia. He aims to find safer and more effective treatments for those whose cancer is harder to treat, enabling more young patients to recover and live healthy lives.
Researchers at UT MD Anderson Cancer Center have made significant progress in treating rare brain infections with a virus-specific T cell therapy, achieving an overall response rate of 56.8% in patients with progressive multifocal leukoencephalopathy (PML). The center also introduced a novel CAR T cell therapy for hard-to-treat kidney ...
Scientists at MD Anderson Cancer Center have identified a previously unknown mechanism by which T cells attack and eliminate acute myeloid leukemia (AML) cells. The discovery reveals that AML cells use a CD64-dependent pathway to evade traditional MHC recognition, potentially explaining why AML is sensitive to immune-based treatments.
Researchers identified a new biological vulnerability in KMT2A-rearranged B-cell acute lymphoblastic leukaemia, which could lead to more effective treatments. Blocking the interaction between two proteins slowed leukaemia progression and enhanced conventional treatment efficacy.
Researchers discovered a new epigenetic therapy that remained effective in treatment-resistant acute myeloid leukemia (AML) through activating the Hippo pathway, a tumor-suppressing pathway linked to cancer growth and drug resistance. The therapy, NTX-301, consistently reduced leukemia cell survival more effectively than existing hypom...
Researchers identified a potential new treatment strategy combining popular weight-loss medications with anti-inflammatory drugs to help patients with obesity-associated leukemia. The study found that obesity creates a state of chronic inflammation that accelerates the growth of mutated, leukemia-causing blood stem cells.
Researchers at Rockefeller University discovered that MLL4 drives disease progression in specific leukemia types while acting as a tumor suppressant in solid tumors. The findings provide new insights into the molecular mechanisms underlying MLL4's context-dependent functions in cancer.
A new strategy makes stem cell transplants safer by replacing chemotherapy-based treatment with targeted antibodies that recognize specific markers on blood-forming stem cells. This approach allows for less toxic treatment and could enable chemotherapy-free or chemotherapy-sparing transplantation approaches.
Researchers identified why some patients with rare blastic plasmacytoid dendritic cell neoplasm (BPDCN) leukemia don't respond to tagraxofusp. Severe TET2 gene mutations and low TXNRD1 enzyme levels contribute to resistance, suggesting these biomarkers could predict treatment outcomes.
A new study by NYU Langone Health researchers reveals how leukemia cells enter the lungs, causing severe breathing problems. Steroid treatment has been shown to improve respiratory function in AML patients with leukemic lung infiltration.
A 57-year-old MDS patient presented with CD34+ micromegakaryocytes and giant platelets in peripheral blood, raising concerns for acute leukemia misdiagnosis. Follow-up studies showed persistent iron-deficiency anemia and easy fatigability, while laboratory results revealed pancytopenia.
Acute leukemias with EWSR1 or FUS gene rearrangements display heterogeneous clinical and pathological characteristics. Cytogenetic karyotyping and fluorescence in situ hybridization remain crucial tools for detecting chromosomal translocations, while advanced molecular diagnostic methods are recommended to improve accurate diagnosis.
A University of Guelph researcher has discovered a common skincare ingredient that may target acute myeloid leukemia by blocking the fat-to-fuel process in cancer cells. The compound inhibits ABCD1 protein production, causing leukemia cells to die while healthy cells adapt and survive.
Two new UH CPRIT grants will accelerate lung cancer prevention, diagnosis, and treatment. Researchers aim to develop new mRNA-based immunotherapies and a next-generation blood test for precise lung cancer detection.
Dr. Josep Maria Ribera receives the EHA Clinical Excellence Award for his distinguished career in Acute Lymphoblastic Leukaemia treatment and patient care improvements. He is also recognized for his academic mentorship, training numerous haematologists who now lead positions in the field.
A recent clinical trial demonstrated that an all-oral drug combination of decitabine-cedazuridine and venetoclax is effective in treating acute myeloid leukemia (AML) in older patients. The regimen showed strong response rates and survival outcomes, with nearly half of patients achieving complete response.
A new study has found that cancers with shrunken genomes are more widespread than previously thought, often associated with highly unstable tumours. Researchers developed a method to distinguish between two leukaemias based on recurring chromosome patterns, offering important clinical insights for patient treatment decisions.
A comprehensive long-term study has demonstrated the efficacy of molecular blood tests in influencing leukemia course. The study found that early intervention based on molecular markers can have a significant impact on disease progression.
Researchers at UT MD Anderson Cancer Center have made significant advancements in cancer care, including the development of a targeted RAS inhibitor therapy for pancreatic cancer and a biomarker of chemotherapy resistance in relapsed lung cancer. The studies also explore the tumor microenvironment of triple-negative breast cancer and i...
Researchers developed a novel algorithm, FUSILLI, to detect gene fusions in B-cell acute lymphoblastic leukemia (B-ALL) using long-read RNA sequencing data. The tool achieves higher diagnostic yield from low-coverage, low-cost sequencing, enabling faster and more accurate diagnosis of pediatric cancer.
Researchers developed a new CAR T cell therapy targeting U5 snRNP200 protein found on AML cells but not healthy blood cells. The approach harnesses antibodies discovered in patients who went into long-term remission after bone marrow transplant, proving effective against several types of leukemia.
Researchers have identified RBPMS as a key player in driving Acute Myeloid Leukemia (AML) progression. The study proposes a novel therapy targeting the FOXO1 protein, which is enhanced by RBPMS, to selectively eliminate leukemia stem cells and improve treatment outcomes.
Researchers at WashU Medicine conducted a clinical trial showing that genetically engineered donor stem cells can prevent toxic side effects and improve treatment options for patients with AML and MDS. The study found that removing the CD33 protein from donor stem cells helped target cancer cells while leaving healthy cells untouched.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
A new study found that targeted maternal screening can prevent adult T-cell leukemia/lymphoma, a rare and aggressive cancer caused by human T-cell leukemia virus type 1. The research identified high disease rates among non-Hispanic Caribbean-born US residents, particularly in Florida and New York.
Researchers developed a novel disease classification system and AI-assisted decision support tool to improve CMML care. The International CMML Prognostic Scoring System (iCPSS) demonstrates superior prognostic discrimination, stratifying patients into five risk groups with different survival outcomes.
Researchers have identified a single genetic change that drives the development of myeloid leukaemia in children with Down Syndrome. The study reveals a common vulnerability and treatment target, suggesting potential repurposed treatments. The genetic change, related to the GATA1 gene, is present at all stages of the disease.
The study projects that cancer rates in Canada will be high in 2026, with declines seen in some cancers like colorectal and leukemia. However, death rates from pancreatic cancer are increasing.
A new study by the Barcelona Supercomputing Center reveals that women's immune systems undergo more pronounced changes with age, leading to a greater susceptibility to autoimmune diseases. In contrast, men experience less extensive immune system changes, but are at higher risk for certain blood cancers.
Four Ontario-based research teams are receiving funding to develop next-generation cancer therapies with improved efficacy and reduced side effects. The projects focus on breast and ovarian cancers, a hard-to-treat form of leukemia, and a 'master regulator' protein involved in many different cancers.
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
Researchers created a CRISPR-based tool to pinpoint genes the cancer turns off, restoring a key cancer-fighting gene in leukemia. The study found that blocking KDM4 enzymes can regain expression of the tumor-suppressor gene ZBTB7A, reducing leukemia burden while leaving normal blood formation largely unaffected.
Researchers developed an interpretable machine learning algorithm, scOMM, to classify cell types consistently across different single-cell methods. The integration strategies and scOMM establish a robust approach for cell atlas generation in complex tissues, leading to the discovery of previously undetected rare cell types.
The Josep Carreras Leukaemia Research Institute is joining forces with the Chinese Institute of Hematology and Blood Diseases Hospital to advance blood cancer research. The partnership aims to develop joint translational research programmes and accelerate the development of curative therapies for patients with blood cancers.
Researchers found that NUTM1 rearranged leukemia is distinct from other forms, with decreased DNA methylation and increased lifespan of blood cells. Leukemias with BRD9-NUTM1 fusion are extremely sensitive to chemotherapy, leading to improved clinical outcomes.
A new national study highlights the genetic changes that link exposure to Agent Orange to myelodysplastic syndromes, a group of bone marrow cancers that can progress to acute leukemia. The research found that exposed veterans were diagnosed at a younger age and had a higher rate of disease progression compared to unexposed patients.
Researchers develop new approach to prevent chemotherapy-related leukemia by analyzing blood samples from four clinical trials, showing a 26-36% reduction in blood cell growth with mutated TP53 gene. They also discover that monoclonal antibodies can turn neutrophils into cancer killers and induce tumor eradication in preclinical models.
Researchers at Albert Einstein College of Medicine have developed a new strategy to engineer immune cells that prolong their effectiveness, addressing a major limitation of current treatments. The new method generates longer-lasting immune cells that provide more sustained control of human blood cancers and suppression of HIV-infection.
A new clinical diagnostic test using optical genome mapping (OGM) has been shown to detect additional genetic variants in nearly 20% of individuals with acute leukemia. OGM offers a comprehensive view of the genome, refining diagnosis and risk stratification, and improving therapy selection. The test's high diagnostic yield and ability...
The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.